Compare PKE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | DSGN |
|---|---|---|
| Founded | 1954 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.4M | 418.1M |
| IPO Year | N/A | 2021 |
| Metric | PKE | DSGN |
|---|---|---|
| Price | $19.24 | $9.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 84.3K | ★ 457.9K |
| Earning Date | 01-13-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 5.81 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $63,128,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.48 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $11.97 | $2.60 |
| 52 Week High | $21.52 | $9.85 |
| Indicator | PKE | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 71.64 |
| Support Level | $18.43 | $8.21 |
| Resistance Level | $19.90 | $9.85 |
| Average True Range (ATR) | 0.70 | 0.68 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 60.89 | 82.97 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.